Category Archives: Re-Vana

Re-Vana Therapeutics Raises $11.9 Million in Series A Financing

Re-Vana Therapeutics Ltd, a privately-held specialty drug delivery company developing sustained-release therapeutics for the treatment of vision-threatening ocular diseases, today announced the closure of its Series A round with $11.9 million in funding, an oversubscription of $4 million. The financing was led by Visionary Ventures. Additional investors include ExSight Ventures, InFocus Capital Partners and existing U.K. investors, Qubis Ltd, Co-Fund NI, and TechStart Ventures. Re-Vana has demonstrated that its groundbreaking platform can achieve 6 months or greater sustained delivery of an anti-VEGF biologic at therapeutically-relevant levels with high drug loading, controlled burst release, and a favorable degradation profile.

Re-Vana Therapeutics Names New Members to the Executive Team

Re-Vana Therapeutics announced the appointment of Michael Nash as Chief Commercial Officer and David Shima, PhD, as Vice President of Research and Development. The two executives will play critical leadership roles at Re-Vana as the company develops innovative sustained release therapies for a broad range of ophthalmic indications, including wet age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma.

Re-Vana in Northern Ireland’s Top 10 Most Innovative Technology Companies

Re-Vana ranks 10th in BusinessCloud’s Northern Ireland Tech 50 ranking for 2020.

Re-Vana Therapeutics Completes of $3.25MM Pre-Series A Financing

Re-Vana Completes $3.25MM Pre-Series A Financing led by Visionary Ventures and ExSight Ventures to Support Pre-clinical Development of Sustained Release Biologic and Small Molecule Therapeutics.